Drug
BI 409306 clinical trials
Also written BI 409306.
- studies test it
- 22
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
22 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 17
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 0
Often tested with
Tested in the same studies.
Donepezil (1) · Itraconazole (1) · Moxifloxacin (1) · Lamotrigine (1) · BI 425809 (1) · Rifampin (1) · BI 498306 (1)
Studies
Open first, then newest update. How each study uses BI 409306 is read from its arms, and is right about nine times in ten.
Testing it · 22
- This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 MonthsTerminatedPhase 2Boehringer IngelheimNCT03351244Written as BI 409306
- This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 YearTerminatedPhase 2Boehringer IngelheimNCT03230097Written as BI 409306
- BI 409306 Cardiac Safety Trial in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02438683Written as BI 409306
- Influence of Fluvoxamine on the Pharmacokinetics of BI 409306CompletedPhase 1Boehringer IngelheimNCT02853136Written as BI 409306 - film coated tablet
- Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female SubjectsCompletedPhase 1Boehringer IngelheimNCT02635750Written as BI 409306
- This Study in Healthy Men and Women Tests How the Body Takes up BI 409306CompletedPhase 1Boehringer IngelheimNCT03505151Written as BI 409306 (C-13/N-15)
- Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02222168Written as BI 409306
- Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01841112Written as BI-409306 25 milligram (mg) SD
- Safety Tolerability and Pharmacokinetic of BI 409306CompletedPhase 1Boehringer IngelheimNCT01343706Written as BI 409306
- Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor MetabolizersCompletedPhase 1Boehringer IngelheimNCT02248259Written as BI 409306
- Safety and Tolerability of BI 409306 in Patients With SchizophreniaCompletedPhase 1Boehringer IngelheimNCT01892384Written as BI 409306
- Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02392468Written as BI 409306 25 mg
- Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT01493570Written as BI 409306
- This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each OtherCompletedPhase 1Boehringer IngelheimNCT03193307Written as BI 409306
- This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)CompletedPhase 1Boehringer IngelheimNCT03934203Written as BI 409306
- A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by KetamineCompletedPhase 1Boehringer IngelheimNCT04602221Written as BI 409306
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising DosesCompletedPhase 1Boehringer IngelheimNCT01505894Written as BI 409306
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306CompletedPhase 1Boehringer IngelheimNCT01611311Written as BI 409306
- Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT03151499Written as BI 409306
- Alzheimer Disease Proof of Concept Study With BI 409306 Versus PlaceboCompletedPhase 2Boehringer IngelheimNCT02240693Written as BI 409306
Codes
What other systems call BI 409306 · ClinicalTrials.gg INT001073
- MeSH (NLM) C000630656BI 409306One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630656 | BI 409306 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.